Table S2.
Comparison of characteristics of patients of derivation cohort vs validation cohort
| Variable | Derivation cohort (n=107) | Validation cohort (n=35) | P-value |
|---|---|---|---|
| Age (years) | 63.0 (54.0, 70.0) | 63.0 (56.5, 68.0) | 0.998 |
| Men (%) | 67 | 21 | 0.458 |
| BSA (m2) | 1.6 (0.2) | 1.6 (0.2) | 0.204 |
| Diagnosis | |||
| COPD | 36 (80.0) | 27 (90.0) | 0.157 |
| ILD | 4 (8.9) | 3 (10.0) | 0.863 |
| Bronchiectasia | 10 (22.2) | 8 (26.7) | 0.962 |
| Other pulmonary diseases with mixed restrictive and obstructive pattern | |||
| CPFE | 1 (2.2) | 1 (3.3) | 0.893 |
| Lobectomia pulmonalis | 4 (8.9) | 0 | 0.229 |
| Chest deformity | 1 (2.2) | 1 (6.7) | 0.320 |
| Emphysema and bullae | 2 (4.4) | 4 (13.3) | 0.228 |
| Lung destruction due to tuberculosis | 3 (6.7) | 1 (3.3) | 0.286 |
| Pneumoconiosis | 1 (2.2) | 0 | 0.452 |
| Sleep-disordered breathing | 1 (2.2) | 0 | 0.356 |
| Alveolar hypoventilation disorders | 2 (4.4) | 0 | 0.452 |
| Comorbidities | |||
| Systemic hypertension | 20 (19.0) | 7 (23.3) | 0.493 |
| Diabetes mellitus | 4 (3.9) | 2 (6.7) | 0.490 |
| Coronary heart disease | 4 (4.8) | 1 (3.3) | 0.420 |
| Malignant tumor | 1 (1.0) | 1 (3.3) | 0.629 |
| Arrhythmia | 10 (9.5) | 2 (6.7) | 0.460 |
| Hyperlipidemia | 3 (2.9) | 2 (6.7) | 0.320 |
| Previous cerebral infarction | 1 (1.0) | 0 | 0.596 |
| Pulmonary function test | |||
| FEV1 % predicted | 32.8 (23.7, 60.4) | 33.0 (20.0, 44.3) | 0.201 |
| FVC % predicted | 53.0 (39.5, 63.3) | 56.4 (43.9, 63.0) | 0.406 |
| FEV1/FVC % predicted | 55.2 (44.5, 69.0) | 45.0 (39.7, 67.5) | 0.067 |
| RV % predicted | 156.9 (106.3, 217.0) | 196.4 (108.1, 304.0) | 0.237 |
| TLC % predicted | 100.5 (80.8, 122.1) | 107.2 (78.3, 135.4) | 0.461 |
| RV/TLC % predicted | 67.2 (53.9, 78.1) | 71.1 (51.0, 79.5) | 0.681 |
| DLco % predicted | 48.9 (26.9, 64.2) | 29.6 (23.5, 53.8) | 0.128 |
| DLco/VA % predicted | 50.8 (27.2, 72.6) | 35.4 (23.2, 66.8) | 0.292 |
Note: Data shown as mean (SD) or median (quartile range).
Abbreviations: BSA, body surface area; ILD, interstitial lung disease; CPFE, combined pulmonary fibrosis and emphysema; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; DLco, diffusing capacity for carbon monoxide; VA, alveolar volume.